tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Porokeratosis D017499 1 associated lipids
Lentigo D007911 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Dysuria D053159 1 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Lung Abscess D008169 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Retrognathia D063173 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Lymphocele D008210 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Lacerations D022125 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Polymyositis D017285 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Nocturia D053158 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Intussusception D007443 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Epididymitis D004823 1 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
Intertrigo D007402 1 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Oral Ulcer D019226 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Mite Infestations D008924 1 associated lipids
Leukoplakia D007971 1 associated lipids
Mutism D009155 1 associated lipids
Akinetic Mutism D000405 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Orchitis D009920 1 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Priapism D011317 1 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Yashima J et al. Successful conversion from tacrolimus to cyclosporine after kidney transplantation. 2000 Transplant. Proc. pmid:11119895
Barrera-Pulido L et al. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications. 2009 Jul-Aug Transplant. Proc. pmid:19715870
Machado PG et al. Use of reduced dose of OKT3 (2.5 mg) after renal transplantation. 2002 Transplant. Proc. pmid:11959207
Sugioka A et al. FK 506 inhibits tolerance induction in mice liver transplantation. 2005 Jan-Feb Transplant. Proc. pmid:15808576
Lemmens HP et al. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis. 1994 Transplant. Proc. pmid:7527983
Propper DJ et al. Effects of the immunosuppressive macrolides rapamycin and FK 506 in high responder rats presensitized to major histocompatibility complex antigens. 1993 Transplant. Proc. pmid:7679837
Jain AB et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721270
Okamura N et al. Enhanced liver regeneration by FK 506 can be blocked by interleukin-1 alpha and interleukin-2. 1992 Transplant. Proc. pmid:1371624
Abu-Elmagd KM et al. Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1721271
Jin MB et al. Protective effect of FK 506 on hepatic energy metabolism in warm ischemic canine livers induced by total hepatic vascular exclusion. 1996 Transplant. Proc. pmid:8623243
Zervos XA et al. Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. 1998 Transplant. Proc. pmid:9636568
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Harihara Y et al. Correlation between graft size and necessary tacrolimus dose after living-related liver transplantation. 2000 Transplant. Proc. pmid:11120116
van Hooff JP et al. Tacrolimus and glucose metabolism. 1999 Transplant. Proc. pmid:10576044
Santos L et al. New-onset diabetes after transplantation: drug-related risk factors. 2012 Transplant. Proc. pmid:23146462
Asano T et al. Increased tacrolimus trough levels in association with severe diarrhea, a case report. 2004 Transplant. Proc. pmid:15518758
Boran M et al. Determining renal resistive and pulsatility indexes long-term after kidney transplantation in kidney transplant recipients on cyclosporine a-, tacrolimus-, or sirolimus-based regimens. 2014 Transplant. Proc. pmid:24935296
Ichimaru N et al. Risk factors and incidence for lipid abnormalities in kidney transplant patients. 2015 Transplant. Proc. pmid:25891708
DiLella AG and Craig RJ Characterization of the human FKBP-12 gene and related pseudogenes. 1991 Transplant. Proc. pmid:1721302
Burke GW et al. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. 1998 Transplant. Proc. pmid:9636627
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Platz KP et al. FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. 1997 Transplant. Proc. pmid:9365598
Masri M et al. Prograf five milligrams versus Tacrolimus medis in healthy volunteers: a bioequivalence study. 2013 Transplant. Proc. pmid:24314930
Laftavi MR et al. African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: does clotrimazole help? 2013 Transplant. Proc. pmid:24314941
Mucha K et al. 36-month follow-up of 75 renal allograft recipients treated with steroids, tacrolimus, and azathioprine or mycophenolate mofetil. 2003 Transplant. Proc. pmid:14529880
Ushigome H et al. Two cases of tacrolimus-induced alopecia following kidney transplantation. 1999 Transplant. Proc. pmid:10578326
Junge G et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. 2005 Transplant. Proc. pmid:15919434
Reggiani P et al. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation. 2005 Transplant. Proc. pmid:15919435
Wilusz M et al. Effect of immunosuppressive therapy on the serum fatty acids of phospholipids fraction in patients after heart transplantation. 2014 Transplant. Proc. pmid:25380928
Huang CT et al. Higher Variability of Tacrolimus Trough Level Increases Risk of Acute Rejection in Kidney Transplant Recipients. Transplant. Proc. pmid:27569931
Ge J et al. Impact of FOXP3 Polymorphisms on the Blood Level of Tacrolimus in Renal Transplant Recipients. Transplant. Proc. pmid:27569929
Kapturczak MH et al. Pharmacology of calcineurin antagonists. 2004 Transplant. Proc. pmid:15041303
Choi SJ et al. Tacrolimus-induced apoptotic signal transduction pathway. 2008 Transplant. Proc. pmid:18929848
Shibutani S et al. FK 506 abrogates induction of regulatory cells after intratracheal delivery of alloantigen. 2002 Transplant. Proc. pmid:12176432
Jin KB et al. Effects of tacrolimus on antioxidant status and oxidative stress in glioma cells. 2008 Transplant. Proc. pmid:18929850
Stockmann M et al. Influence of immunosuppressive drugs on intestinal epithelial transport function. 2002 Transplant. Proc. pmid:12176434
Lee TK et al. Bacterial translocation and the role of postoperative selective bowel decontamination in small intestinal transplantation. 1994 Transplant. Proc. pmid:7518154
Hranjec T et al. Benign transient hyperphosphatasemia associated with Epstein-Barr virus enteritis in a pediatric liver transplant patient: a case report. 2008 Transplant. Proc. pmid:18589195
Grossi P et al. Infectious complications in experimental small bowel transplantation. 1994 Transplant. Proc. pmid:7518155
Santiago SF et al. Effect of short-term immunosuppressive therapy with FK 506 or CyA on the donor in small intestine allotransplantation in rats. 1992 Transplant. Proc. pmid:1376520
Tanaka M et al. Effect of anticomplement agent K-76 COOH in hamster-to-rat and guinea pig-to-rat xenotransplantation. 1995 Transplant. Proc. pmid:7533392
Utsunomiya H et al. Effect of FK 506 on orthotopic small bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376521
Tsugita M et al. Prevention of sensitization and hyperacute rejection in liver and heart xenografts by FK 506 plus donor antigens. 1995 Transplant. Proc. pmid:7533393
Winkler M et al. Use of FK 506 for treatment of chronic rejection after liver transplantation. 1991 Transplant. Proc. pmid:1721334
D'Alessandro AM et al. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. 1991 Transplant. Proc. pmid:1721335
Altaca G et al. Effect of low-dose calcineurin inhibitors on acute rejection and graft survival. 2002 Transplant. Proc. pmid:12270320
Pohanka E et al. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients. 2005 Transplant. Proc. pmid:15919490
Marqués E et al. Development of lymphoproliferative disease after liver transplantation. 2008 Transplant. Proc. pmid:19010169
Squifflet JP et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. 2002 Transplant. Proc. pmid:12176495
Boggi U et al. Neoral versus prograf in simultaneous pancreas-kidney transplantation with portal venous drainage: three-year results of a single-center, open-label, prospective, randomized pilot study. 2005 Jul-Aug Transplant. Proc. pmid:16182772
Kamei T et al. Established intraportal islet allograft is rejected despite the acceptance of donor-specific second cardiac allograft. 1992 Transplant. Proc. pmid:1281579
Ko WJ et al. Clinical trial of FK506 in heart transplant patients in Taiwan: report of 7 cases with immunosuppression switch from cyclosporine to FK506. 1998 Transplant. Proc. pmid:9838474
Offner G et al. FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. 1991 Transplant. Proc. pmid:1721366
Kociszewska-Najman B et al. Congenital Infections in Neonates of Women With Liver or Kidney Transplants. 2016 Transplant. Proc. pmid:27496446
Imai K et al. Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. 1991 Transplant. Proc. pmid:1703347
Cho JH et al. Chronic rejection in pediatric liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123078
Spada M et al. Bacterial translocation is enhanced in pig intestinal transplantation when the colon is included in the graft. 1996 Transplant. Proc. pmid:8907997
Takayama K et al. Nonmuscle myosin heavy chain and nuclear factor-kappa B expression in pig-to-primate xenotransplanted hearts. 2000 Transplant. Proc. pmid:10936372
Goller AL et al. Loss of serum bicarbonate after discordant liver xenotransplantation. 2000 Transplant. Proc. pmid:10936383
Boots JM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. 2002 Transplant. Proc. pmid:12176542
Suzuki H et al. Spleen grafting might induce transplantation tolerance in rats. 1995 Transplant. Proc. pmid:7536973
Ji SM et al. Conversion from cyclosporine to tacrolimus for chronic allograft nephropathy. 2007 Transplant. Proc. pmid:17580148
Yang HC et al. Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation--1-year follow-up of a prospective, randomized clinical trial. 1999 Feb-Mar Transplant. Proc. pmid:10083501
Sakamoto K et al. Analysis of long-term acceptance of xenografts in rats induced by short-term administration of FK506. 1989 Transplant. Proc. pmid:2468222
Moutabarrik A et al. Use of FK 506 in kidney transplantation. 1993 Transplant. Proc. pmid:7685946
Nakajima K et al. Effects of 15-deoxyspergualin and FK506 on the histology and survival of hamster-to-rat cardiac xenotransplantation. 1989 Transplant. Proc. pmid:2468223
Galvao FH et al. Experimental animal model of graft-versus-host disease (GVHD) after small-bowel transplantation: characteristics of the model and application to developing treatment strategies. 1997 Feb-Mar Transplant. Proc. pmid:9123488
Falconer SJ et al. Conversion from twice-daily to once-daily tacrolimus in simultaneous pancreas-kidney transplant patients. 2014 Transplant. Proc. pmid:24935313
Kimura O et al. Influence of bombesin on the intestinal mucosal immunologic response under immunosuppression. 2000 Transplant. Proc. pmid:10995942
Gibelli NE et al. Sirolimus in pediatric liver transplantation: a single-center experience. 2009 Transplant. Proc. pmid:19376384
Kamar N et al. Efficacy and safety of induction therapy with rabbit antithymocyte globulins in liver transplantation for hepatitis C. 2004 Transplant. Proc. pmid:15621141
Dette K et al. Daclizumab and ATG versus ATG in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous [correction of simultaneus] pancreas-kidney transplantation: analysis of early outcome. 2002 Transplant. Proc. pmid:12176624
Baran DA et al. Can initial tacrolimus trough levels be predicted from clinical variables? 2004 Transplant. Proc. pmid:15621157
Zaltzman J et al. Tacrolimus, MMF, steroid, and ALG immunotherapy for high immunological risk renal transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267183
Sahara H et al. Thymectomy does not abrogate long-term acceptance of MHC class I-disparate lung allografts in miniature Swine. 2006 Transplant. Proc. pmid:17175240
El-Safa EA et al. Paradoxical response to tacrolimus assessed by interleukin-2 gene expression. 2006 Transplant. Proc. pmid:17175263
de Bruin RW et al. Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721429
Kawabe A et al. Anti-adhesion (anti-ICAM-1 and anti-LFA-1) therapy in a rat pancreas transplantation model. 1996 Transplant. Proc. pmid:8658893
Langrehr JM et al. FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. 1991 Transplant. Proc. pmid:1721430
Hayakawa K et al. Maintenance of unresponsiveness by short-term pulse therapy with FK 506 in rat transplantation. 1996 Transplant. Proc. pmid:8658904
Moura Neto A et al. Frequency of Thyroid Dysfunction in Patients With Diabetes Mellitus Before and After Liver Transplantation. 2018 Transplant. Proc. pmid:29661439
Goto T et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. 1987 Transplant. Proc. pmid:2445072
Zeevi A et al. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. 1987 Transplant. Proc. pmid:2445073
Burrows L et al. Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients. 1998 Transplant. Proc. pmid:9723378
Donadio C et al. Tubular damage and impairment of renal function in transplanted kidneys. 1998 Transplant. Proc. pmid:9723381
Demir T et al. Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy. 2015 Transplant. Proc. pmid:26093731
Rabkin JM et al. Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267411
Deguchi K et al. Effects of FK 506 on acute experimental allergic encephalomyelitis. 1991 Transplant. Proc. pmid:1721461
Lee CM et al. Monotherapy with tacrolimus for heart and liver transplant: a case report. 2014 Transplant. Proc. pmid:24767396
McAlister VC Liposomal tacrolimus: drug migration within blood compartments. 1998 Transplant. Proc. pmid:9636404
Gotsman I et al. Effect of peripheral immune tolerance on liver-associated lymphocytes expressing NK1.1. 2000 Transplant. Proc. pmid:10856569
Malinowski K et al. Effect of different anti-rejection regimens on the expression of differentiation and activation markers on the surface of host lymphocytes. 2000 Transplant. Proc. pmid:10856579
Socci C et al. Pancreata from pediatric donors restore insulin independence in adult insulin-dependent diabetes mellitus recipients. 2010 Jul-Aug Transplant. Proc. pmid:20692410
Matsumoto S et al. ET-Kyoto ductal injection and density-adjusted purification combined with potent anti-inflammatory strategy facilitated single-donor islet transplantation: case reports. 2010 Jul-Aug Transplant. Proc. pmid:20692433
Blume C et al. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients. 2001 Nov-Dec Transplant. Proc. pmid:11750357
Jørgensen KA et al. Optimal time for determination of blood tacrolimus level. 2001 Nov-Dec Transplant. Proc. pmid:11750358
Morris RE et al. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. 1991 Transplant. Proc. pmid:1703698
Busque S et al. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. 1998 Transplant. Proc. pmid:9636507
Loss GE et al. Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. 1998 Transplant. Proc. pmid:9636508